Cathestatin and metabolic syndrome in patients with hypertension
https://doi.org/10.31146/1682-8658-ecg-235-3-152-157
Abstract
Metabolic syndrome (MS) is a common comorbid condition in patients with hypertension (HTN), associated with an increased risk of cardiovascular complications. The role of catestatin (CST), a chromogranin A breakdown product with vasodilatory, cardioprotective, and metabolic properties, has attracted growing interest. The aim of this review is to analyze current data on the relationship between CST and MS components in patients with HTN. A systematic search was conducted in the PubMed, Scopus, and Web of Science databases. A total of 18 original studies (a total sample of 2,547 patients) met the inclusion criteria. It was shown that reduced CST level is associated with the presence of MS (odds ratio 2.47; 95% confidence interval 1.83-3.34), abdominal obesity (r= -0.38; p<0.001), insulin resistance (r= -0.29; p<0.01) and dyslipidemia (r= -0.25; p<0.05) regardless of gender, age and duration of hypertension. CST can be considered as a potential biomarker of MS and a therapeutic target in patients with high cardiometabolic risk.
About the Authors
L. Yu. Shvan
Samara State Medical University
Russian Federation
Russian Federation
I. V. Gubareva
Samara State Medical University
Russian Federation
Russian Federation
S. A. Tokarev
Samara State Medical University
Russian Federation
Russian Federation
E. Yu. Gubareva
Samara State Medical University
Russian Federation
Russian Federation
References
1. Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation. 2009;120(16):1640-1645.
2. Ellulu M.S., Patimah I., Khaza’ai H., Rahmat A., Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851-863.
3. Gu Q., Paulose-Ram R., Burt V.L., Kit B.K. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no 177. Hyattsville, MD: National Center for Health Statistics. 2014.
4. Mahata S.K., Kiranmayi M., Mahapatra N.R. Catestatin: A Master Regulator of Cardiovascular Functions. Curr Med Chem. 2018;25(11):1352-1374.
5. Markov A.G., Ovchinnikova E.S., Shen Y. et al. The Role of Catestatin in the Regulation of Cardiovascular and Metabolic Functions. Front Neurosci. 2019;13:1094.
6. Meng L., Ye X.J., Ding W.H., Yang Y., Di B.B., Liu H.J. Plasma catestatin level in patients with acute coronary syndrome and its correlation with ventricular remodelling. Postgrad Med J. 2011;87(1033):688-693.
7. Owen M.K., Noblet J.N., Sassoon D.J., Conteh A.M., Goodwill A.G., Tune J.D. Perivascular adipose tissue and coronary vascular disease. Arterioscler Thromb Vasc Biol. 2014;34(8):1643-1649.
8. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399-2403.
9. Reinehr T. Metabolic Syndrome in Children and Adolescents: a Critical Approach Considering the Interaction between Pubertal Stage and Insulin Resistance. Curr Diab Rep. 2016;16(1):8.
10. Shah S.H., Newgard C.B.Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ Cardiovasc Genet. 2015;8(2):410-419.
11. Vanhoutte P.M., Shimokawa H., Feletou M., Tang E.H.C. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219(1):22-96.
12. Wang D., Govindaiah A., Liu R., De Arcangelis V., Cox C.L., Xiang Y.K. Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity. FASEB J. 2010;24(9):3511-3521.
13. Yoo Y.M., Lee C.J., Lee U., Kim Y.J. Nobiletin enhances adiponectin secretion from differentiated 3T3-L1 adipocytes via a MEK/ERK-dependent pathway. Biochem Biophys Res Commun. 2017;483(1):511-517.
14. Zhang X., Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61-73.
15. Zhu Y., Liu Q., Zhou Z., Ikeda Y. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 2017;8(1):240.
Review
For citations:
Shvan L.Yu., Gubareva I.V., Tokarev S.A., Gubareva E.Yu. Cathestatin and metabolic syndrome in patients with hypertension. Experimental and Clinical Gastroenterology. 2025;(3):152-157. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-235-3-152-157
Views:
2
Email this article 